SCHEMBL20488209

SCHEMBL20488209

Cc1ccc(S(=O)(=O)n2ccc3c(CO)ccnc32)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.55
CYP19A1 P11511 1/20 0.45
PTGDR2 Q9Y5Y4 1/20 0.44
RAPGEF4 Q8WZA2 2/20 0.41
HTR6 P50406 5/20 0.41
PKM P14618 1/20 0.40
CYP2C19 P33261 1/20 0.40
POLB P06746 1/20 0.39
ALDH3A1 P30838 1/20 0.39
HTT P42858 1/20 0.39
NOD1 Q9Y239 1/20 0.39
AGTR1 P30556 1/20 0.39
ALK Q9UM73 1/20 0.38
VEGFA P15692 1/20 0.38
EGLN1 Q9GZT9 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
KDM4E B2RXH2 1/20 0.38
UBE2N P61088 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29375543 0.87 L3MBTL1 (0.55) L3MBTL1CYP19A1PTGDR2RAPGEF4HTR6
SCHEMBL22502433 0.87 L3MBTL1 (0.55) L3MBTL1CYP19A1PTGDR2RAPGEF4HTR6
SCHEMBL3797786 0.84 L3MBTL1 (0.48) L3MBTL1CYP19A1PTGDR2RAPGEF4HTR6
SCHEMBL29378984 0.83 L3MBTL1 (0.51) L3MBTL1CYP19A1PTGDR2RAPGEF4HTR6
SCHEMBL22502398 0.83 L3MBTL1 (0.51) L3MBTL1CYP19A1PTGDR2RAPGEF4HTR6
SCHEMBL28927986 0.83 L3MBTL1 (0.59) L3MBTL1PTGDR2RAPGEF4HTR6PKM
SCHEMBL2237896 0.82 L3MBTL1 (0.62) L3MBTL1CYP19A1PTGDR2RAPGEF4HTR6
SCHEMBL1749202 0.82 L3MBTL1 (0.62) L3MBTL1CYP19A1PTGDR2RAPGEF4HTR6
SCHEMBL2024287 0.82 HTR6 (0.56) L3MBTL1CYP19A1PTGDR2HTR6POLB
SCHEMBL12272025 0.81 L3MBTL1 (0.56) L3MBTL1PTGDR2RAPGEF4HTR6PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3589618-B1 PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2022-12-28 EP disclosed
EP-3589618-B1 PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2022-12-28 EP disclosed
US-10966961-B2 Pyrazole derivatives as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2021-04-06 US disclosed
US-10966961-B2 Pyrazole derivatives as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2021-04-06 US disclosed
WO-2018158212-A1 PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10966961-B2 Pyrazole derivatives as bromodomain inhibitors BRD3, BRD4, BRPF3 L3MBTL1 4020/4885CYP19A1 2331/4885PTGDR2 737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.